# Sun Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sun-genomics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.sungenomics.com
- Total disclosed funding: $21M
- Latest round: Series A (Sep 16, 2020)
- Investors on record: 8

## About

Sun Genomics, Inc. develops and delivers personalized probiotics that enhance gut health through customized formulations based on individual microbiome profiles and health surveys.Founded in 2016 and headquartered in San Diego, US, Sun Genomics specializes in personalized health solutions. The CEO and founder, Suneer Jain, has a background in health technology. In September 2020, the company secured USD 9.25 mn in Series A funding led by Pangaea Ventures, along with participation from several other investors, marking a significant milestone in its growth trajectory.Floré by Sun Genomics focuses on personalized probiotic solutions aimed at improving gut health. Their offerings include customized probiotic formulations created from individual microbiome testing and health surveys, addressing a range of gut-related health issues such as bloating and digestive discomfort. Floré serves a diverse customer base, including individuals with specific health needs, with products available in both capsule and powder forms.Floré's revenue model is subscription-based, where customers begin by completing a health and diet survey, which, when combined with microbiome test results, results in tailored probiotic formulations. This model fosters ongoing consumer relationships as users are encouraged to retest their microbiome after six months for formulation adjustments. The flagship products include "Floré Mood" and "Floré Pathways", each designed for specific health needs, reflecting the customization and scientific backing of their offerings.With the recent raise of USD 9.25 mn in Series A funding on September 16, 2020, Sun Genomics plans to enhance its product line and expand into new geographic markets. The funding will support the development of new probiotic formulations, with targeted launches aimed at regions across North America and Europe. The company aims to utilize this investment to solidify its market presence and further tailor its products to meet the needs of a growing customer base.

## Funding rounds

- Series A, Sep 16, 2020, $9.3M — Pangaea Ventures, SOSV, Emerging Technologies Ltd, Human Longevity, Inc., Danone Manifesto Ventures, Nascita Ventures LLC, K3 Ventures
- Series A, May 11, 2020, $8.7M — Pangaea Ventures, SOSV, Human Longevity, Inc., Danone Manifesto Ventures, Nascita Ventures LLC
- Seed, Dec 21, 2018, $3M — SOSV
- Seed, Dec 6, 2017 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed, Series A
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed
- Pangaea Ventures (https://capitalatlas.ai/funds/pangaea-ventures) — Series A
- Human Longevity, Inc. — Series A
- Danone Manifesto Ventures (https://capitalatlas.ai/funds/danone-manifesto-ventures) — Series A
- Nascita Ventures LLC — Series A
- Emerging Technologies Ltd — Series A
- K3 Ventures (https://capitalatlas.ai/funds/k3-ventures) — Series A